Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer

Clinical Trial ID NCT01069640

Rank	Title	Journal	Year	PubWeight™‹?›
1	Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.	Cancer Sci	2009	1.49
2	Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.	Cancer Res	2007	1.42
3	Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.	Cancer Sci	2007	1.35
4	Trial watch: Peptide vaccines in cancer therapy.	Oncoimmunology	2012	1.17
5	Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis.	Cancer Res	2006	1.12
6	Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma.	Cancer Sci	2008	1.11
7	HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.	Int J Cancer	2008	1.10
8	From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma.	Gen Thorac Cardiovasc Surg	2008	0.89